THC.CSE THCBF – OTC TFHD.F
Vancouver, Canada – July 6, 2023 – THC BioMed Intl Ltd. (“THC BioMed” or the “Company“), a pioneer in the cannabis industry and one of the leaders in scientific research and development of products and services, is pleased to announce that it has begun shipping its premium Pre-Rolls to the province of British Columbia.
In addition, THC BioMed is thrilled to share that its recently introduced Summer Gummy product line has been approved for distribution by the province. This marks a significant milestone for the Company as it continues to expand its product offerings and solidify its presence in the dynamic cannabis market.
“We are thrilled to extend our portfolio of products to consumers in British Columbia,” says John Miller, CEO. “With the shipment of our Pre-Rolls and the approval of our exciting new Summer Gummy line, we aim to meet the diverse needs of our customers while delivering high-quality, innovative products that stay true to our core values.”
THC BioMed is renowned for its commitment to offering a range of premium cannabis products designed to cater to the unique preferences of medical patients and recreational consumers alike. The Company’s pre-rolls, known for their superior quality, and the recently introduced Summer Gummy line, are prime examples of this ongoing commitment.
As THC BioMed continues to broaden its reach across the Canadian market, the Company remains focused on its mission to provide safe, effective, and accessible cannabis products to its customers.
For additional information about THC BioMed’s product lines or to stay updated on the Company’s latest developments, visit www.thcbiomed.com.
For more information, media inquiries, or partnership opportunities, please contact:
President and CEO: John Miller
About THC BioMed
THC BioMed Intl Ltd. is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services related in the medical cannabis industry. Patient safety is not merely a goal but a guiding principle for THC BioMed.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. Forward-looking statements in this release include that the Company will continue to broaden its reach across the Canadian market. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.